LFCR Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -32.12% compared to Lifecore Biomedical, Inc.'s net margin of -255.85%. Lifecore Biomedical, Inc.'s return on equity of -70.33% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Lifecore Biomedical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 12.61%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Lifecore Biomedical, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Lifecore Biomedical, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Lifecore Biomedical, Inc. has a beta of 0.599, which suggesting that the stock is 40.067% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Lifecore Biomedical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Lifecore Biomedical, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Lifecore Biomedical, Inc. quarterly revenues are $31.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Lifecore Biomedical, Inc.'s net income of -$10M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Lifecore Biomedical, Inc.'s price-to-earnings ratio is 133.20x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical, Inc. is 2.09x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics, Inc. has a net margin of -32.12% compared to Lifecore Biomedical, Inc.'s net margin of --. Lifecore Biomedical, Inc.'s return on equity of -70.33% beat Oragenics, Inc.'s return on equity of -509.23%.

Lifecore Biomedical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 12.61%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 134.85%. Given that Oragenics, Inc. has higher upside potential than Lifecore Biomedical, Inc., analysts believe Oragenics, Inc. is more attractive than Lifecore Biomedical, Inc..

Lifecore Biomedical, Inc. has a beta of 0.599, which suggesting that the stock is 40.067% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.

Lifecore Biomedical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifecore Biomedical, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

Lifecore Biomedical, Inc. quarterly revenues are $31.1M, which are larger than Oragenics, Inc. quarterly revenues of --. Lifecore Biomedical, Inc.'s net income of -$10M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Lifecore Biomedical, Inc.'s price-to-earnings ratio is 133.20x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical, Inc. is 2.09x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -32.12% compared to Lifecore Biomedical, Inc.'s net margin of --. Lifecore Biomedical, Inc.'s return on equity of -70.33% beat Palatin Technologies's return on equity of --.

Lifecore Biomedical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 12.61%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Lifecore Biomedical, Inc., analysts believe Palatin Technologies is more attractive than Lifecore Biomedical, Inc..

Lifecore Biomedical, Inc. has a beta of 0.599, which suggesting that the stock is 40.067% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Lifecore Biomedical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifecore Biomedical, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Lifecore Biomedical, Inc. quarterly revenues are $31.1M, which are larger than Palatin Technologies quarterly revenues of --. Lifecore Biomedical, Inc.'s net income of -$10M is higher than Palatin Technologies's net income of --. Notably, Lifecore Biomedical, Inc.'s price-to-earnings ratio is 133.20x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical, Inc. is 2.09x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -32.12% compared to Lifecore Biomedical, Inc.'s net margin of --. Lifecore Biomedical, Inc.'s return on equity of -70.33% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Lifecore Biomedical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 12.61%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2797.35%. Given that Theriva Biologics, Inc. has higher upside potential than Lifecore Biomedical, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Lifecore Biomedical, Inc..

Lifecore Biomedical, Inc. has a beta of 0.599, which suggesting that the stock is 40.067% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Lifecore Biomedical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifecore Biomedical, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Lifecore Biomedical, Inc. quarterly revenues are $31.1M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Lifecore Biomedical, Inc.'s net income of -$10M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Lifecore Biomedical, Inc.'s price-to-earnings ratio is 133.20x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical, Inc. is 2.09x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.